{"id":6670,"date":"2026-05-15T19:46:00","date_gmt":"2026-05-15T17:46:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=630af32a23e2fc4a608280fb57b6e83f"},"modified":"2026-05-15T19:46:00","modified_gmt":"2026-05-15T17:46:00","slug":"secretome-therapeutics-announces-participation-in-upcoming-summer-investor-conferences","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=6670","title":{"rendered":"Secretome Therapeutics Announces Participation in Upcoming Summer Investor Conferences"},"content":{"rendered":"

\nCompany to attend Jefferies, Oppenheimer, and Cantor investor conferences focused on the biopharma sector<\/b><\/p><\/a><\/a>

PLANO, Texas--(BUSINESS WIRE)--#Biotech<\/a>--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that members of its management team will participate in three upcoming investor conferences this summer.<\/p>

\nSecretome is scheduled to attend the following conferences:<\/p>

\nJefferies Global Healthcare Conference\n<\/b>June 2 \u2013 4, 2026\nNew York, New York<\/p>

\nOppenheimer CNS & Neuro-Muscular Summit\n<\/b>June 10, 2026\nMiami, FL<\/p>

\nCantor Global Healthcare Conference\n<\/b>September 9 \u2013 11, 2026\nNew York, New York<\/p>

\nDuring the conferences, Secretome management will meet with investors and industry participants to discuss the company\u2019s clinical-stage nCPC-based therapeutic platform, its lead program STM-01, and its development strategy in serious cardiovascular diseases with high unmet need.<\/p>

\n\u201cWe look forward to participating in these upcoming investor conferences and engaging with the healthcare investment community as we continue to advance STM-01 and our broader pipeline,\u201d said Vinny Jindal, President and Chief Executive Officer of Secretome Therapeutics. \u201cThese meetings provide an important opportunity to share our progress, including our work to develop STM-01 for Duchenne muscular dystrophy-associated cardiomyopathy and other forms of heart failure.\u201d<\/p>

\nSecretome is advancing STM-01, its lead neonatal cardiac progenitor cell therapy, for Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM), dilated cardiomyopathy, and heart failure with preserved ejection fraction. The company is also developing a broader pipeline of nCPC-based therapeutic programs for orphan and underserved chronic diseases.<\/p>

\nAbout Secretome Therapeutics<\/b><\/p>

\nSecretome Therapeutics is a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPCs) for orphan and underserved chronic diseases. Its lead program, STM-01, is being advanced for Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM), alongside a broader pipeline of nCPC-based therapeutic programs.<\/p>

\nForward-Looking Statements<\/b><\/p>

\nThis press release contains forward-looking statements, including statements regarding anticipated conference participation, investor engagement, future corporate updates, development timing, and planned clinical and regulatory milestones. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties.<\/p> Contacts<\/b>

\nVinny Jindal\nPresident and CEO\nvjindal@secretometx.com<\/a>https:\/\/secretometherapeutics.com\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Company to attend Jefferies, Oppenheimer, and Cantor investor conferences focused on the biopharma sectorPLANO, Texas–(BUSINESS WIRE)–#Biotech–Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based t…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6670","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/6670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6670"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/6670\/revisions"}],"predecessor-version":[{"id":6671,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/6670\/revisions\/6671"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}